BeOne Medicines (ONC) Stock Price, News & Analysis

BeOne Medicines logo
$390.94 -8.76 (-2.19%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$390.72 -0.21 (-0.05%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About BeOne Medicines Stock (NASDAQ:ONC)

Advanced

Key Stats

Today's Range
$385.00
▼
$399.76
50-Day Range
$346.50
▼
$424.00
52-Week Range
$253.95
▼
$424.73
Volume
356,778 shs
Average Volume
460,593 shs
Market Capitalization
$42.92 billion
P/E Ratio
49.67
Dividend Yield
N/A
Price Target
$441.64
Consensus Rating
Buy

Company Overview

BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia.

Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer. BeOne also develops additional oncology treatments through a broad research and clinical development pipeline.

Co-founder John V. Oyler serves as the company’s chairman and chief executive officer.

AI Generated. May Contain Errors.

BeOne Medicines Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
82nd Percentile Overall Score

ONC MarketRank™: 
4.09708737864 of 5 stars

BeOne Medicines scored higher than 82% of companies evaluated by MarketBeat, and ranked 124th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BeOne Medicines has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 16 buy ratings, 1 hold rating, and no sell ratings.

  • Upside Potential

    BeOne Medicines has a consensus price target of $441.64, representing about 13.0% upside from its current price of $390.94.

  • Amount of Analyst Coverage

    BeOne Medicines has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about BeOne Medicines' stock forecast and price target.
  • Earnings Growth

    Earnings for BeOne Medicines are expected to grow by 40.58% in the coming year, from $9.98 to $14.03 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BeOne Medicines is 49.67, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.26.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BeOne Medicines is 49.67, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.53.

  • Price to Book Value per Share Ratio

    BeOne Medicines has a P/B Ratio of 7.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.56% of the float of BeOne Medicines has been sold short.
  • Short Interest Ratio / Days to Cover

    BeOne Medicines has a short interest ratio ("days to cover") of 4.37.
  • Change versus previous month

    Short interest in BeOne Medicines has recently decreased by 10.61%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    BeOne Medicines does not currently pay a dividend.

  • Dividend Growth

    BeOne Medicines does not have a long track record of dividend growth.

  • News Sentiment

    BeOne Medicines has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for BeOne Medicines this week, compared to 6 articles on an average week.
  • Search Interest

    8 people have searched for ONC on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added BeOne Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BeOne Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $48,487,792.00 in company stock.

  • Percentage Held by Insiders

    6.19% of the stock of BeOne Medicines is held by insiders.

  • Percentage Held by Institutions

    48.55% of the stock of BeOne Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about BeOne Medicines' insider trading history.
Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeOne Medicines and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ONC Stock News Headlines

$0. Later: $29.97.
Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.tc pixel
Up 15% since October: Inside the oncology stock beating healthcare
See More Headlines

ONC Stock Analysis - Frequently Asked Questions

BeOne Medicines' stock was trading at $303.81 at the beginning of the year. Since then, ONC shares have increased by 28.7% and is now trading at $390.94.

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) issued its earnings results on Thursday, November, 5th. The company reported $3.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.34 by $1.30. The firm had revenue of $1.89 billion for the quarter, compared to analysts' expectations of $1.76 billion. BeOne Medicines had a net margin of 13.86% and a trailing twelve-month return on equity of 19.04%.
Read the conference call transcript
.

BeOne Medicines (ONC) raised $152 million in an IPO on Wednesday, February 3rd 2016. The company issued 6,600,000 shares at $22.00-$24.00 per share.

BeOne Medicines' top institutional investors include Baker BROS. Advisors LP (8.04%), First Trust Advisors LP (0.29%), Candriam S.C.A. (0.26%) and Goldman Sachs Group Inc. (0.18%). Insiders that own company stock include Bros Advisors Lp Baker, John Oyler, Xiaodong Wang, Titus B Ball, Chan Henry Lee, Xiaobin Wu, Margaret Dugan, Lai Wang, Lai Wang, Corazon (Corsee) D Sanders, Corazon (Corsee) D Sanders, Alessandro Riva and Aaron Rosenberg.
View institutional ownership trends
.

Shares of ONC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BeOne Medicines investors own include NVIDIA (NVDA), Micron Technology (MU), Bloom Energy (BE), Citigroup (C), Celestica (CLS), Coherent (COHR) and Arista Networks (ANET).

Company Calendar

Last Earnings
11/05/2026
Today
11/21/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ONC
Previous Symbol
NASDAQ:ONC
CIK
1651308
Fax
N/A
Employees
12,000
Year Founded
N/A

Price Target and Rating

High Price Target
$484.91
Low Price Target
$367.00
Potential Upside/Downside
+13.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
18 Analysts

Profitability

EPS (Trailing Twelve Months)
$7.87
Trailing P/E Ratio
49.67
Forward P/E Ratio
27.86
P/E Growth
N/A
Net Income
$286.93 million
Net Margins
13.86%
Pretax Margin
17.12%
Return on Equity
19.04%
Return on Assets
10.70%

Debt

Debt-to-Equity Ratio
0.14
Current Ratio
3.55
Quick Ratio
3.19

Sales & Book Value

Annual Sales
$5.34 billion
Price / Sales
8.03
Cash Flow
$3.72 per share
Price / Cash Flow
105.23
Book Value
$53.01 per share
Price / Book
7.37

Miscellaneous

Outstanding Shares
109,790,000
Free Float
102,991,000
Market Cap
$42.92 billion
Optionable
Optionable
Beta
0.63
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:ONC) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners